RE:To NASDAQ or Not to NASDAQ. That's the question !
Instead of wasting money and time, diluting shareholders' for NASDAQ listing , why not scrap the plan, focus on improving Trogarzo and Egrifta sales, publish NASH trial results, design HIV NASH trial to submit to the FDA, further the new cancer treatment pipeline into trial and above all, strike a general NASH partnership with a big pharma ?
With the upfront payment from the partnership deal, issue a one-time divident to force the shorts pay for it.